Elicio Therapeutics (ELTX) Profit After Tax (2020 - 2026)

Elicio Therapeutics has reported Profit After Tax for 7 years, with the latest figure at -$11.8 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 5.48% year-over-year to -$11.8 million; the trailing twelve-month figure through Mar 2026 stood at -$40.2 million (up 21.64% YoY), and the FY2025 full-year result was -$39.6 million, up 23.75% from the prior year.
• Profit After Tax for Q1 2026 stood at -$11.8 million, down from -$7.7 million in the prior quarter.
• The five-year high for Profit After Tax was -$6.7 million in Q4 2022, with the low at -$18.8 million in Q3 2024.
• Historically, Profit After Tax has averaged -$9.8 million across 5 years, with a median of -$8.9 million in 2023.
• The largest YoY upside for Profit After Tax was 80.76% in 2022 against a maximum downside of 144.67% in 2022.
• Elicio Therapeutics' Profit After Tax stood at -$6.7 million in 2022, then tumbled by 34.55% to -$8.9 million in 2023, then slumped by 56.49% to -$14.0 million in 2024, then jumped by 44.89% to -$7.7 million in 2025, then slumped by 53.19% to -$11.8 million in 2026.
• The last three Profit After Tax figures came in at -$11.8 million (Q1 2026), -$7.7 million (Q4 2025), and -$10.1 million (Q3 2025), per Business Quant data.